137 results on '"sjogren syndrome"'
Search Results
2. SAFETY AND TOLERANCE OF ANTI-SARS-COV-2 VACCINES IN SJÖGREN'S SYNDROME: RESULTS FROM THE COVAD STUDY.
3. LIFESTYLE AND NUTRITIONAL STATUS IN ITALIAN PATIENTS WITH ISOLATED SJÖGREN'S SYNDROME.
4. CORRELATION BETWEEN PATHOLOGICAL FINDINGS AND SALIVARY GLAND ULTRASOUND IN PATIENTS WITH CLINICAL SUSPICION OF SJÖGREN'S SYNDROME IN A TERTIARY HOSPITAL.
5. CHRONIC SCLEROSING SIALADENITIS, IS IT A SJÖGREN'S SYNDROME OR NOT?
6. MYOSITIS IN PRIMARY SJÖGREN'S SYNDROME: DATA FROM A MULTICENTRE COHORT.
7. PERIPHERAL PLATELET-GENERATING MEGAKARYOCYTE REDUCED IN PRIMARY SJÖGREN'S SYNDROME.
8. PREDICTIVE PARAMETERS FOR THE DEVELOPMENT OF PERIPHERAL NEUROPATHIES IN PRIMARY SJÖGREN'S SYNDROME.
9. INDIRECT HEALTH RELATED COST IN PSS PATIENTS IN RELATION TO SYMPTOM BASED ENDOTYPES.
10. THE SIGNIFICANCE OF A COMPREHENSIVE EXAMINATION OF DRY EYE DISEASE IN PRIMARY SJÖGREN SYNDROME AND ITS RELATIONSHIP TO EXTRAOCULAR MANIFESTATIONS.
11. NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: A RETROSPECTIVE CROSS-SECTIONAL STUDY.
12. THE ASSOCIATION OF NEUROPATHIC PAIN WITH LOWER URINARY SYMPTOM SEVERITY IN PRIMARY SJÖGREN'S PATIENTS.
13. THE MENTAL HEALTH IMPACT OF SEXUAL DYSFUNCTION IN SJÖGREN'S DISEASE: A SOCIAL MEDIA APPROACH TO REAL-WORLD EVIDENCE.
14. THE FOLLOW-UP OF PSS PATIENTS WITH PERIPHERAL NEUROLOGIC INVOLVEMENT IN A TERTIARY CENTER.
15. DEFINING INTERFERON MEDIATED CONDITIONS (DEFINITION): IFN ASSAYS AND CLINICAL FEATURES OF ESTABLISHED ANA-ASSOCIATED AUTOIMMUNE DISEASES.
16. LOW-DOSE IL-2 CHANGED THE PROPRTION OF LYMPHOCYTE SUBSETS IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME.
17. PRIMARY SJÖGREN'S SYNDROME AND INTERSTITIAL LUNG DISEASE. RESULTS OF AN OBSERVATIONAL COHORT.
18. TREATMENT OF PRIMARY SJÖGREN'S SYNDROME BY INHIBITING FCRN: A PHASE 2 RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, PROOF OF CONCEPT STUDY WITH EFGARTIGIMOD.
19. ASSOCIATION OF SELF-PERCEIVED ORAL HEALTH STATUS WITH ESSPRI REPORTED BY PATIENTS WITH SJÖGREN'S SYNDROME.
20. VARIATION IN SYSTEMIC DISEASE ACTIVITY MEASURED WITH ESSDAI IN A PROSPECTIVE LONGITUDINAL COHORT OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME WITHOUT IMMUNOSUPPRESSIVE TREATMENT.
21. EXTRAGLANDULAR INVOLVEMENT AND AUTOANTIBODY STATUS AS RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PRIMARY SJÖGREN'S SYNDROME (PSS): A 20-YEAR FOLLOW-UP STUDY.
22. IMMUNOEMATHOLOGIC FEATURES IN A COHORT OF PEDIATRIC PATIENTS WITH SJÖGREN'S SYNDROME: AN OVERLAP WITH AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS)-LIKE DISORDERS.
23. MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN'S SYNDROME.
24. THE WEIGHT OF ANTI-LA/SSB ANTIBODIES IN RO/SSA-POSITIVE PATIENTS WITH A NEWLY DIAGNOSED SJÖGREN'S SYNDROME: A PHENOTYPE CHARACTERIZED BY A MORE SEVERE MAJOR AND MINOR GLANDULAR INVOLVEMENT AND A HIGHER BIOLOGICAL ACTIVITY.
25. CLINICAL COURSE AND RISK FACTORS FOR DEVELOPMENT AND PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PRIMARY SJÖGREN'S SYNDROME: A SINGLE-CENTERED, RETROSPECTIVE, OBSERVATIONAL STUDY.
26. INTERSTITIAL LUNG DISEASE IN SJOGREN'S SYNDROME: PREVALENCE, PATTERNS, TREATMENT, AND PROGNOSIS.
27. PROGRESSIVE PULMONARY FIBROSIS ACCORDING TO THE NEW ATS DEFINITION IS NOT UNCOMMON IN THE CONTEXT OF SJÖGREN'S SYNDROME-ASSOCIATED INTERSTITIAL LUNG DISEASE.
28. 3-YEAR ANALYSES OF AT-RISK ANA-POSITIVE COHORT: PROGNOSTIC VALUE OF CLINICAL AND INTERFERON BIOMARKERS TOWARDS AUTOIMMUNITY.
29. "IF I HAVE SJÖGREN'S SYNDROME, I WANT TO KNOW IT AS EARLY AS POSSIBLE": PERSPECTIVES OF FIRST-DEGREE RELATIVES OF PEOPLE WITH SJÖGREN'S SYNDROME FROM AN INTERNATIONAL SURVEY.
30. IMMUNE CELLS AND THEIR EFFECTOR FUNCTIONS IN NEONATES BORN TO ANTI-RO/LA POSITIVE WOMEN.
31. SECRETAGOGUE EFFECT OF PDE4 INHIBITOR APREMILAST ON HUMAN SALIVARY GLAND ORGANOIDS OBTAINED FROM PRIMARY SJÖGREN'S SYNDROME PATIENTS.
32. DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME.
33. THE RISK OF INFLUENZA IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASESFOCUS ON PRIMARY SJOGREN'S SYNDROME, POLYMYOSITIS/DERMATOMYOSITIS AND SYSTEMIC SCLEROSIS.
34. INCREASED INCIDENCE OF SJÖGREN'S SYNDROME IN THE FEMALE PATIENTS WITH HASHIMOTO THYROIDITIS: A LARGE PROPENSITY SCOREMATCHED COHORT STUDY.
35. PREGNANCY IN CONNECTIVE TISSUE DISEASES: A 30 YEAR FOLLOW-UP STUDY OF 465 PREGNANCIES FROM A SPANISH MONOCENTRIC REGISTRY.
36. DEEP LEARNING BASED ASSESSMENT OF SALIVARY GLAND ULTRASONOGRAPHY IMAGES FOR SUPPORTING THE DIAGNOSIS OF PRIMARY SJOGREN'S SYNDROME.
37. DIFFERENTIALLY EXPRESSED GENES (DEGS) OVERLAPPED FROM DATASETS FROM PATIENTS WITH SJÖGREN'S SYNDROME (SS) THROUGH INTEGRATIVE BIOINFORMATICS ANALYSIS DISPLAY INTERFERON SIGNATURE.
38. THE ROLE OF IGG N-LINKED SIALYLATION AND GALACTOSYLATION IN PRIMARY SJÖGREN'S SYNDROME IN ITS POTENTIAL AS A MARKER OF DISEASE STATE AND DISEASE ACTIVITY.
39. ALTERATION OF ILC HOMEOSTASIS MAINLY CONCERNS SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME.
40. CD40L BLOCKADE WITH DAZODALIBEP (VIB4920/HZN4920) REDUCES BLOOD BIOMARKERS OF T AND B CELL COSTIMULATION IN SUBJECTS WITH SYSTEMIC SJÖGREN'S SYNDROME.
41. HIGH DIMENSIONAL CARTOGRAPHY OF LYMPHOCYTES USING SINGLE-CELL MASS CYTOMETRY DIFFERENTIATES SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY SJÖGREN'S SYNDROME.
42. T FOLLICULAR HELPER CELLS IN BLOOD MIRROR SALIVARY GLAND-INFILTRATING T CELLS IN PRIMARY SJÖGREN'S SYNDROME.
43. MICA/B-DEPENDENT ACTIVATION OF CYTOTOXIC NATURAL KILLER CELLS BY INFLAMMATORY CDC2 CONTRIBUTE TO PRIMARY SJÖGREN'S SYNDROME PATHOLOGY.
44. COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN SJÖGREN'S SYNDROME: RESULTS FROM THE COVAD STUDY.
45. "I LOST A PART OF ME": A QUALITATIVE STUDY EXPLORING THE IMPACTS OF SJÖGREN'S SYNDROME ON THE SEXUAL LIVES AND INTIMATE RELATIONSHIPS OF WOMEN WITH THE CONDITION.
46. DETERMINATION OF DISTINCT PHENOTYPES OF PRIMARY SJÖGREN'S DISEASE USING CLUSTER ANALYSIS BASED ON CLINICAL AND BIOLOGICAL MANIFESTATIONS: DATA FROM 458 PATIENTS FROM THE PARIS SACLAY SJÖGREN'S SYNDROME COHORT.
47. CHARACTERIZATION OF PULMONARY MANIFESTATIONS OF SJÖGREN SYNDROME: A MULTICENTER RETROSPECTIVE STUDY.
48. IMPACT OF LYMPHOMA TREATMENT STRATEGY ON HEMATOLOGIC RESPONSE AND AUTOIMMUNE DISEASE ACTIVITY IN SJOGREN PATIENTS DEVELOPING LYMPHOMA.
49. DEEP LEARNING ACCURATELY PREDICTS FOCUS SCORE AND DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME USING LABIAL SALIVARY GLAND BIOPSIES.
50. EXAMINING CLINICAL HETEROGENEITY IN PRIMARY SJOGREN'S SYNDROME: PROTEOMIC AND NETWORK ANALYSIS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.